ONS Receives Educational Grants to Fund Conferences

Publication
Article
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

The Oncology Nursing Society (ONS) recently received grants from Genentech, Inc., to fund two educational projects. A $96,000 grant will fund the ONS National Conference on Cancer Nursing Research to be held in 1999, and a $30,930 grant

The Oncology Nursing Society (ONS) recently received grants from Genentech, Inc., to fund two educational projects. A $96,000 grant will fund the ONS National Conference on Cancer Nursing Research to be held in 1999, and a $30,930 grant will support the Outcomes Research State-of-the-Knowledge Conference to be held later this year.

The goal of the ONS National Conference on Cancer Nursing Research is to bridge the gap between nursing research and practice and create a forum for scholarly exchange. The objectives of the conference are to:

1) discuss state-of-the-art research;

2) examine research outcomes in selected areas of cancer nursing practice;

3) evaluate the application of research findings to cancer nursing practice, education, and policy; and

4) review the application of state-of-the-art research methodologies as they pertain to the study of selected aspects of cancer.

The conference will include plenary and concurrent sessions, a poster session, and roundtable breakfasts so that participants can meet and talk with the speakers.

The Outcomes Research State-of-the-Knowledge Conference will be an invitational meeting based on a competitive review of submitted abstracts. The presentations will focus on identifying and defining nurse-sensitive oncology outcomes, discussing research design and methodologic issues, and addressing future research directions and funding priorities.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content